Sophisticated analytical technologies are complementing traditional approaches in the identification of residual process-related impurities of biotherapeutics.
Stuart Pengelley
Advertisement
Stuart Pengelley is the senior scientist, Biopharma Application Development for Bruker Daltonics.
Articles by Stuart Pengelley
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on BioPharm International
1
FDA Accepts BLA for Formycon and Zydus’ FYB206, the First Publicly Announced Keytruda Biosimilar Under Review
2
FDA Rare Disease Framework Initiative: What It Means for Drug and Biologic Development
3
FDA Expands Anktiva Approval to Papillary-Only BCG-Unresponsive Bladder Cancer
4
Gilead Taps Vir Biotechnology's PRO-XTEN Tech for Solid Tumors
5